Another trial (phase 3, CheckMate-649) evaluated Nivolumab (PD-1 inhibitor) in combination with chemotherapy versus chemotherapy alone for patients with GEJ, EAC, gastric cancer (HER2 negative), supporting an improved OS [64]. This evidence concerns the gene ERBB2 and gastric cancer.